Combinatory Cancer Therapeutics with Nanoceria-Capped Mesoporous Silica Nanocarriers through pH-triggered Drug Release and Redox Activity

dc.contributor.authorSingh, Rajendra K.en
dc.contributor.authorPatel, Kapil D.en
dc.contributor.authorMahapatra, Chinmayaen
dc.contributor.authorParthiban, S. Prakashen
dc.contributor.authorKim, Tae Hyunen
dc.contributor.authorKim, Hae Wonen
dc.date.accessioned2025-05-30T23:33:16Z
dc.date.available2025-05-30T23:33:16Z
dc.date.issued2019-01-09en
dc.description.abstractIn the field of nanomedicine, drug-loaded nanocarriers that integrate nanotechnology and chemotherapeutics are widely used to achieve synergistic therapeutic effects. Here, we prepared mesoporous silica nanoparticles capped with cerium oxide nanoparticles (COP@MSN) wherein a pH trigger-responsive mechanism was used to control drug release and intracellular drug delivery. We blocked the mesopores of the carboxyl-functionalized MSN with aminated COP. These pores could be opened in acidic conditions to release the loaded drug, thus establishing a pH-responsive drug release system. We loaded doxorubicin (DOX) as anticancer biomolecule into the pores of MSN and capped with COP. The COP@DOX-MSN system showed a typical drug release profile in an acidic medium, which, however, was not observed in a neutral medium. In vitro studies using cancer cell line (HeLa) proved that the COP@DOX-MSN entered efficiently into HeLa cells and released DOX to the level sufficient for cytotoxicity. The cytotoxic effect of COP in cancer cells was facilitated by the pro-oxidant property of COPs, which considerably raised the reactive oxygen species (ROS) level, thereby leading to cellular apoptosis. The combination of DOX with COP (COP@DOX-MSN) showed even higher ROS level, demonstrating a cytotoxic synergism of drug and nanoparticle in terms of ROS generation. Collectively, the COP@DOX-MSN is considered useful for cancer treatment with the combined capacity of pH-controlled drug delivery, chemotherapeutics, and redox activity.en
dc.description.sponsorshipThis work was supported by the grants from National Research Foundation (Nos 2015032163, 2016936387, 2017R1C1B1011387, 2018R1D1A1B07048020, and 2018K1A4A3A01064257), Republic of Korea.en
dc.description.statusPeer-revieweden
dc.format.extent12en
dc.identifier.issn1944-8244en
dc.identifier.otherPubMed:30539634en
dc.identifier.otherORCID:/0000-0002-0393-9166/work/171153386en
dc.identifier.scopus85059854528en
dc.identifier.urihttp://www.scopus.com/inward/record.url?scp=85059854528&partnerID=8YFLogxKen
dc.identifier.urihttps://hdl.handle.net/1885/733755633
dc.language.isoenen
dc.rightsPublisher Copyright: © 2018 American Chemical Society.en
dc.sourceACS Applied Materials and Interfacesen
dc.subjectcapping agenten
dc.subjectcerium oxideen
dc.subjectcontrolled drug deliveryen
dc.subjectmesoporous silicaen
dc.subjectpH-responsiveen
dc.titleCombinatory Cancer Therapeutics with Nanoceria-Capped Mesoporous Silica Nanocarriers through pH-triggered Drug Release and Redox Activityen
dc.typeJournal articleen
dspace.entity.typePublicationen
local.bibliographicCitation.lastpage299en
local.bibliographicCitation.startpage288en
local.contributor.affiliationSingh, Rajendra K.; Dankook Universityen
local.contributor.affiliationPatel, Kapil D.; Dankook Universityen
local.contributor.affiliationMahapatra, Chinmaya; Dankook Universityen
local.contributor.affiliationParthiban, S. Prakash; Dankook Universityen
local.contributor.affiliationKim, Tae Hyun; Dankook Universityen
local.contributor.affiliationKim, Hae Won; Dankook Universityen
local.identifier.citationvolume11en
local.identifier.doi10.1021/acsami.8b17958en
local.identifier.puref7e99751-35b5-4df2-b51c-f11e4bcf89fben
local.identifier.urlhttps://www.scopus.com/pages/publications/85059854528en
local.type.statusPublisheden

Downloads